EUVIMEDDescubrir EUVIMED
CrossrefTarjeta informativa

Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model ( LSL‐Kras G12D/+ ;LSL‐Trp53 R172H/+ ;Pdx‐1‐Cre ), Its Variants, and Their Application in Immuno‐oncology Drug Discovery

Jae W. Lee, Chad A. Komar, Fee Bengsch, Kathleen Graham, Gregory L. Beatty

Current Protocols in Pharmacology · 2016-06 · 73 (1)

DOI: 10.1002/cpph.2 ↗
ResumenDatos bibliográficos

Resumen

Abstract Pancreatic ductal adenocarcinoma (PDAC) ranks fourth among cancer‐related deaths in the United States. For patients with unresectable disease, treatment options are limited and lack curative potential. Preclinical mouse models of PDAC that recapitulate the biology of human pancreatic cancer offer an opportunity for the rational development of novel treatment approaches that may improve patient outcomes. With the recent success of immunotherapy for subsets of patients with solid malignancies, interest is mounting in the possible use of immunotherapy for the treatment of PDAC. Considered in this unit is the value of genetic mouse models for characterizing the immunobiology of PDAC and for investigating novel immunotherapeutics. Several variants of these models are described, all of which may be used in drug development and for providing information on unique aspects of disease biology and therapeutic responsiveness. © 2016 by John Wiley & Sons, Inc.

Conocimiento que se adapta a su trabajo.

Desde un inicio gratuito y la búsqueda bibliográfica personal hasta la Research Suite completa.

Ver tarifas →

¿Se incluyen todos los textos completos editoriales?

No. Registros, resúmenes y textos completos son contenidos diferentes. La disponibilidad depende de la fuente, del acceso abierto y de sus licencias. Un plan EUVIMED no sustituye derechos editoriales adicionales.

Ver tarifas →